The most common forms of extended difficulty were feelings of anxiety and fear, existential struggle, social disconnection, depersonalization and derealization.

For approximately one-third of the participants, problems persisted for over a year, and for a sixth, they endured for more than three years.

It was found that a shorter duration of difficulties was predicted by knowledge of dose, drug type and lower levels of difficulty reported during the psychoactive experience, while a narrower range of difficulties was predicted by taking the drug in a guided setting.

Intensity of Psychedelic Experience

November 8, 2023 Lynne Nardizzi

A new study suggests that dosage, age, and neuroticism may predict the intensity of a psychedelic experience, whether mystical (positive) or challenging.

The War on Drugs and How it Damages the Environment

November 7, 2023 Lynne Nardizzi

The criminalization of drug production and consumption is driving widespread environmental damage and impeding efforts to stop climate change, a new report from The International Coalition on Drug Policy Reform & Environmental Justice warned today, in advance of the International Drug Policy Reform Conference and less than two months before the UN Climate Change Conference in Dubai.

The report unveils how prohibitive drug policies – which drive drug cultivation into remote and incredibly fragile ecosystems to evade law enforcement detection – are undermining environmental progress and governance in the world’s tropical forest frontiers.

Psychedelics for Addiction?

November 6, 2023 Lynne Nardizzi

Here’s an interview on psychedelics and addiction recovery, five questions for physician Peter Grinspoon.

Grinspoon discusses recovery, addiction and whether psychedelics might have a role in addiction treatment.

HPPD: Hallucinogen-Persisting Perception Disorder

November 2, 2023 Lynne Nardizzi

Here’s a look at HPPD, the persistence of psychedelic-like perceptual phenomena after the acute effects of a psychedelic have worn off. It may be rare, but it is a risk and not well understood.

Psilocybin and Adverse Childhood Experiences

October 23, 2023 Lynne Nardizzi

In this new study, findings suggest that psilocybin therapy may be potentially acceptable and may feasibly help in supporting survivors of adverse childhood experiences with particularly strong benefits to those with more severe childhood adversity.

Psychedelics for OCD?

October 22, 2023 Lynne Nardizzi

A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.

False Insights with Psychedelics

October 21, 2023 Lynne Nardizzi

Psychedelic insights are thought to be highly valuable and therapeutic—but can they be false?

Researchers suggest this is sometimes the case.

The Colors of Sound

October 20, 2023 Lynne Nardizzi

Different colors of noise could actually help you feel and function better.

Which may be why YouTube videos and other social media posts about the benefits of exposure to pink, green, brown, white and other types of noise are trending.

Colored noises are having a major moment.

When Wellness Becomes Toxic

October 17, 2023 Lynne Nardizzi

Here’s a great outlook on the wellness industry, and how marketing becomes more important than actually helping people.

Psychedelics and Chronic Pain

October 6, 2023 Lynne Nardizzi

A new study published in the European Journal of Pain last month found that both macro and micro doses of classic psychedelics — LSD, psilocybin, DMT, mescaline — led to better pain relief compared to conventional medication in volunteers surveyed.

Blog

A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.